Hikma Pharmaceuticals (LON:HIK) Hits New 1-Year Low – Should You Sell?

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as GBX 1,353 and last traded at GBX 1,391.08, with a volume of 3827154 shares changing hands. The stock had previously closed at GBX 1,652.

More Hikma Pharmaceuticals News

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Group revenue and profit grew for FY2025 and the board announced a share buyback and leadership changes — these are supportive actions that can bolster shareholder value. Article Title
• Neutral Sentiment: Management highlighted strong EBITDA and other operating metrics in the full-year earnings call, but those positives were largely outweighed by cautious guidance. Article Title
• Neutral Sentiment: The board named the company chair as chief executive in a leadership change — this concentrates leadership but its long-term effect will depend on execution. Article Title
• Negative Sentiment: Management warned of slower growth and cut forward guidance, triggering a sharp sell-off as investors reassessed the outlook. Article Title
• Negative Sentiment: Analysts and markets focused on a margin warning that accompanies the results — margins were weaker than hoped, prompting heavy selling. Article Title
• Negative Sentiment: Multiple reports describe the company’s outlook as “gloomy” and note the shares hitting multi-year lows after the guidance cut. Article Title
• Negative Sentiment: Market summaries note the stock underperformed the broader market as the guidance and margin concerns dominated headlines. Article Title
• Negative Sentiment: Commentary highlights that despite in-line results, the guidance cut caused large downside reaction and heavy intraday volume. Article Title

Analyst Ratings Changes

HIK has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a research report on Friday, January 9th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 2,300 target price on shares of Hikma Pharmaceuticals in a report on Thursday, January 22nd. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday, November 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Finally, Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of GBX 2,326.

Hikma Pharmaceuticals Stock Down 1.4%

The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The company has a market cap of £3.00 billion, a P/E ratio of 8.11, a P/E/G ratio of 2.38 and a beta of 0.41. The stock has a 50 day moving average price of GBX 1,558.47 and a 200 day moving average price of GBX 1,645.26.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.